Delivering anti-HIV antibodies directly to the body for protection
Official title: Vectored delivery of anti-HIV antibodies for mucosal protection
Funded at University of Miami School of Medicine · NIH-11030809 · Data updated 2026-11-12
This study is exploring a new way to deliver strong anti-HIV antibodies directly into the body using a special virus, aiming to provide lasting protection against HIV without needing regular shots, and it's designed for people living with HIV who are looking for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | March 14, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $1 |
| NIH project number | 5R01AI176522-03 |
| Project ID | NIH-11030809 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of HIV exposure or those living with HIV who may benefit from enhanced mucosal immunity.
✕Less likely to help
Patients who are not at risk for HIV or those who have already developed advanced stages of HIV/AIDS may not receive benefit from this research.
What this research studies
This research investigates a novel method of delivering potent anti-HIV antibodies directly to the body using adeno-associated virus (AAV) vectors. By bypassing the immune system, the goal is to achieve long-term protection against HIV without the need for frequent injections. The study focuses on the use of polymeric immunoglobulins, which have unique properties that may enhance mucosal protection against the virus. Previous animal studies have shown promise, and early human trials have indicated safety and feasibility.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting and effective method for protecting individuals from HIV infection.
How similar studies have gone: Previous studies using AAV vectors for antibody delivery have shown promising results in animal models and initial human trials, indicating a potential for success in this approach.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Martinez-Navio, Jose Maria — University of Miami School of Medicine
- Study coordinator: Martinez-Navio, Jose Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.